<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941174</url>
  </required_header>
  <id_info>
    <org_study_id>1000008487-2b</org_study_id>
    <nct_id>NCT00941174</nct_id>
  </id_info>
  <brief_title>Folate Absorption Across the Large Intestine</brief_title>
  <official_title>Folate Absorption Across the Large Intestine, Study #2: Capsule Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether the intact human colon with an unaltered
      microflora distribution absorbs folate and to what extent it is absorbed into the systemic
      circulation using a dual/oral intravenous route. This will elicit an understanding of colonic
      folate absorption and metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study supplements two earlier in print exploratory studies investigating the absorption
      of folate across the colon after an infusion during colonoscopy and a pre-trial with the
      purpose of determining dissolution characteristics of two placebo caplet formulations. Using
      a dual route oral/intravenous, folate (pharmaceutical name Calcium Leucovorin), labeled with
      a stable isotope will be used to quantitatively measure total folate levels, as well as the
      uptake of (13C) labeled folate. A pH dependent caplet targeted to the colon and fluoroscopy
      will determine dissolution characteristics. Labeled and unlabelled folate in blood and urine
      samples will be used to quantitatively measure the uptake of folate. This will further our
      understanding of the kinetics (caplet transit times), colonic folate absorption (metabolism)
      and impact on folate status (bioavailability) in healthy adults.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Folate - Study Period 1</measure>
    <time_frame>Day 1 (Baseline), Day 2 (0h,1h,2h,3h,4h,5h,6h,7h,8h,9h,10h,11h,12h,24hr,48hr)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Folate - Study Period 2</measure>
    <time_frame>Day 2 (0h, 0.25h,0.5h,1h,1.5h,2h,2.5h,3h,3.5h,4h)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Folate - Study Period 1</measure>
    <time_frame>24h, 48h, 72h, 96h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine Folate - Study Period 2</measure>
    <time_frame>24h, 48h, 72h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dietary Recall Records for folate analysis during urine collection days, Anthropometric.</measure>
    <time_frame>Study Phase 1 (Day 2,Day 3,Day 4,Day 5) Study Period (Day 2,Day 3,Day 4)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Capsule: 400 microg 13C5-Calcium-L-Leucovorin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13C5-Calcium-L-Leucovorin</intervention_name>
    <description>This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.</description>
    <arm_group_label>Capsule: 400 microg 13C5-Calcium-L-Leucovorin</arm_group_label>
    <arm_group_label>IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin</arm_group_label>
    <other_name>13C5 Folate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults

          2. Age 18-65 years

        Exclusion Criteria

          1. &lt;18 years of age, &gt;65 years of age

          2. chronic disease (eg. history of hepatic, gastrointestinal, renal, vascular,
             hematological, or neuropsychiatric disease) or surgery affecting gastrointestinal
             motility, pH or folate absorption/metabolism

          3. regular use of medications affecting gastrointestinal pH, motility or folate
             absorption/metabolism (eg. anti-acid or nonsteroidal anti-inflammatory drugs [NSAIDS]
             such as aspirin/ibuprofen, phenytoin, sulfasalazine, phenobarbital, primidone, and
             cimetidine)

          4. regularly consume &gt; 1 drink of alcohol/d or current smoking (last 6 months)

          5. planning a pregnancy, pregnant, breast feeding or the use of high-dose oral
             contraceptives/hormone replacement therapy

          6. known sensitivity to Calcium Leucovorin

          7. 130mL of blood is &gt; 5% of total blood volume
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah O'Connor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital For Sick Chidlren</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <last_update_submitted>December 30, 2013</last_update_submitted>
  <last_update_submitted_qc>December 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Deborah O'Connor</investigator_full_name>
    <investigator_title>Associate Chief, Clinical Dietetics</investigator_title>
  </responsible_party>
  <keyword>(13C5) Calcium Leucovorin</keyword>
  <keyword>Folate absorption across the large intestine</keyword>
  <keyword>Folate Bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

